AG˹ٷ

STOCK TITAN

[Form 4] Simon Property Group, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. (TMO) filed a Form 4 on July 1, 2025 disclosing that director Jennifer M. Johnson was credited with 76.54 phantom stock units on June 28, 2025 under the company’s Deferred Compensation Plan for Directors. The units, valued at $408.28 each, convert to common stock on a 1-for-1 basis when the director leaves the board or upon a change of control. After the credit, Johnson holds 474.05 stock-equivalent units, all recorded as direct ownership.

The transaction represents routine deferral of quarterly board retainer fees rather than an open-market purchase or sale. With an estimated market value of roughly $31 thousand, the filing is financially immaterial relative to Thermo Fisher’s multi-billion-dollar market capitalization. No options were exercised, no common shares were sold, and the company’s share count and cash position remain unchanged. The filing nevertheless reinforces incentive alignment by tying a portion of Johnson’s compensation to future shareholder returns.

Thermo Fisher Scientific Inc. (TMO) ha presentato un Modulo 4 il 1° luglio 2025, rivelando che la direttrice Jennifer M. Johnson ha ricevuto 76,54 unità di azioni fantasma il 28 giugno 2025 nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le unità, valutate ciascuna 408,28 $, si convertono in azioni ordinarie con un rapporto 1:1 al momento dell'uscita della direttrice dal consiglio o in caso di cambio di controllo. Dopo l'accredito, Johnson detiene 474,05 unità equivalenti ad azioni, tutte registrate come proprietà diretta.

La transazione rappresenta un differimento ordinario delle commissioni trimestrali del consiglio, e non un acquisto o vendita sul mercato aperto. Con un valore di mercato stimato di circa 31 mila $, la comunicazione è finanziariamente irrilevante rispetto alla capitalizzazione di mercato multimiliardaria di Thermo Fisher. Non sono state esercitate opzioni, non sono state vendute azioni ordinarie e il numero di azioni e la posizione di cassa della società rimangono invariati. Tuttavia, la comunicazione rafforza l'allineamento degli incentivi legando una parte della remunerazione di Johnson ai futuri rendimenti per gli azionisti.

Thermo Fisher Scientific Inc. (TMO) presentó un Formulario 4 el 1 de julio de 2025, informando que la directora Jennifer M. Johnson recibió 76,54 unidades de acciones fantasma el 28 de junio de 2025 bajo el Plan de Compensación Diferida para Directores de la empresa. Las unidades, valoradas en $408,28 cada una, se convierten en acciones comunes en una proporción 1 a 1 cuando la directora deja la junta o en caso de un cambio de control. Tras el acreditamiento, Johnson posee 474,05 unidades equivalentes a acciones, todas registradas como propiedad directa.

La transacción representa un aplazamiento rutinario de las tarifas trimestrales del consejo, no una compra o venta en el mercado abierto. Con un valor de mercado estimado de aproximadamente $31 mil, la presentación es financieramente insignificante en relación con la capitalización de mercado multimillonaria de Thermo Fisher. No se ejercieron opciones, no se vendieron acciones comunes y la cantidad de acciones y la posición de efectivo de la empresa permanecen sin cambios. Sin embargo, la presentación refuerza la alineación de incentivos al vincular una parte de la compensación de Johnson con los futuros rendimientos para los accionistas.

Thermo Fisher Scientific Inc. (TMO)� 2025� 7� 1일에 제출� Form 4� 통해 이사 Jennifer M. Johnson� 2025� 6� 28� 회사� 이사 지� 보상 계획� 따라 76.54 가� 주식 단위� 부여받았음� 공개했습니다. � 단위� $408.28� 가치가 있으�, 이사가 이사회에� 물러나거� 지배권 변� � 1대 1 비율� 보통주로 전환됩니�. 이번 부� � Johnson은 � 474.05 주식 등가 단위� 보유하고 있으�, 모두 직접 소유� 기록되어 있습니다.

이번 거래� 분기� 이사� 보수� 정기� 이연� 나타내며, 공개 시장에서� 매매가 아닙니다. � $31�� 추정 시가총액으로 Thermo Fisher� 수십� 달러 규모 시장가치에 비해 재무적으� 미미� 수준입니�. 옵션 행사� 없었�, 보통� 매도� 없었으며 회사� 주식 수와 현금 상태� 변동이 없습니다. 그럼에도 이번 제출은 Johnson� 보상 일부� 미래 주주 수익� 연계하여 인센티브 정렬� 강화합니�.

Thermo Fisher Scientific Inc. (TMO) a déposé un formulaire 4 le 1er juillet 2025, révélant que la directrice Jennifer M. Johnson a reçu 76,54 unités d'actions fantômes le 28 juin 2025 dans le cadre du Plan de rémunération différée pour les administrateurs de la société. Ces unités, valorisées à 408,28 $ chacune, se convertissent en actions ordinaires au taux de 1 pour 1 lorsque la directrice quitte le conseil d'administration ou en cas de changement de contrôle. Après cet attribution, Johnson détient 474,05 unités équivalentes en actions, toutes enregistrées en propriété directe.

Cette opération représente un report habituel des honoraires trimestriels du conseil d'administration, et non un achat ou une vente sur le marché ouvert. Avec une valeur marchande estimée à environ 31 000 $, cette déclaration est financièrement négligeable par rapport à la capitalisation boursière multimilliardaire de Thermo Fisher. Aucune option n’a été exercée, aucune action ordinaire vendue, et le nombre d’actions ainsi que la trésorerie de la société restent inchangés. Néanmoins, cette déclaration renforce l’alignement des incitations en liant une partie de la rémunération de Johnson aux futurs rendements pour les actionnaires.

Thermo Fisher Scientific Inc. (TMO) reichte am 1. Juli 2025 ein Formular 4 ein und gab bekannt, dass die Direktorin Jennifer M. Johnson am 28. Juni 2025 76,54 Phantomaktieneinheiten im Rahmen des Deferred Compensation Plans für Direktoren erhalten hat. Die Einheiten, die jeweils mit 408,28 $ bewertet sind, werden bei Ausscheiden der Direktorin aus dem Vorstand oder bei einem Kontrollwechsel im Verhältnis 1:1 in Stammaktien umgewandelt. Nach der Gutschrift hält Johnson 474,05 aktienäquivalente Einheiten, die alle als Direktbesitz verbucht sind.

Die Transaktion stellt eine routinemäßige Aufschiebung der vierteljährlichen Vorstandsvergütung dar und ist kein Kauf oder Verkauf am freien Markt. Bei einem geschätzten Marktwert von rund 31.000 $ ist die Meldung im Verhältnis zur milliardenschweren Marktkapitalisierung von Thermo Fisher finanziell unerheblich. Es wurden keine Optionen ausgeübt, keine Stammaktien verkauft, und die Anzahl der Aktien sowie die Liquiditätslage des Unternehmens bleiben unverändert. Die Meldung stärkt jedoch die Anreizstruktur, indem ein Teil von Johnsons Vergütung an zukünftige Aktionärsrenditen gekoppelt wird.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine deferred-comp acquisition; negligible size, neutral impact.

The Form 4 records quarterly board-fee deferral into 76.54 phantom units, lifting the director’s stake to 474.05 units. Because phantom stock is settled only after service ends, there is no immediate liquidity event or cash flow. The $31k market value is immaterial to both the insider and TMO’s capital structure. From a governance standpoint, continued equity linkage is positive for alignment but not large enough to influence sentiment or valuation. I assign a neutral impact rating.

TL;DR: Insignificant position increase; no trading signal.

Johnson’s phantom stock credit under the director plan is administrative, not opportunistic buying. Volume (76.54 units) is de minimis versus TMO’s average daily volume and implies no informational edge. The filing does not alter supply-demand dynamics or forward fundamentals; therefore, I view the market impact as non-existent and maintain a neutral stance on the shares.

Thermo Fisher Scientific Inc. (TMO) ha presentato un Modulo 4 il 1° luglio 2025, rivelando che la direttrice Jennifer M. Johnson ha ricevuto 76,54 unità di azioni fantasma il 28 giugno 2025 nell'ambito del Piano di Compensazione Differita per i Direttori della società. Le unità, valutate ciascuna 408,28 $, si convertono in azioni ordinarie con un rapporto 1:1 al momento dell'uscita della direttrice dal consiglio o in caso di cambio di controllo. Dopo l'accredito, Johnson detiene 474,05 unità equivalenti ad azioni, tutte registrate come proprietà diretta.

La transazione rappresenta un differimento ordinario delle commissioni trimestrali del consiglio, e non un acquisto o vendita sul mercato aperto. Con un valore di mercato stimato di circa 31 mila $, la comunicazione è finanziariamente irrilevante rispetto alla capitalizzazione di mercato multimiliardaria di Thermo Fisher. Non sono state esercitate opzioni, non sono state vendute azioni ordinarie e il numero di azioni e la posizione di cassa della società rimangono invariati. Tuttavia, la comunicazione rafforza l'allineamento degli incentivi legando una parte della remunerazione di Johnson ai futuri rendimenti per gli azionisti.

Thermo Fisher Scientific Inc. (TMO) presentó un Formulario 4 el 1 de julio de 2025, informando que la directora Jennifer M. Johnson recibió 76,54 unidades de acciones fantasma el 28 de junio de 2025 bajo el Plan de Compensación Diferida para Directores de la empresa. Las unidades, valoradas en $408,28 cada una, se convierten en acciones comunes en una proporción 1 a 1 cuando la directora deja la junta o en caso de un cambio de control. Tras el acreditamiento, Johnson posee 474,05 unidades equivalentes a acciones, todas registradas como propiedad directa.

La transacción representa un aplazamiento rutinario de las tarifas trimestrales del consejo, no una compra o venta en el mercado abierto. Con un valor de mercado estimado de aproximadamente $31 mil, la presentación es financieramente insignificante en relación con la capitalización de mercado multimillonaria de Thermo Fisher. No se ejercieron opciones, no se vendieron acciones comunes y la cantidad de acciones y la posición de efectivo de la empresa permanecen sin cambios. Sin embargo, la presentación refuerza la alineación de incentivos al vincular una parte de la compensación de Johnson con los futuros rendimientos para los accionistas.

Thermo Fisher Scientific Inc. (TMO)� 2025� 7� 1일에 제출� Form 4� 통해 이사 Jennifer M. Johnson� 2025� 6� 28� 회사� 이사 지� 보상 계획� 따라 76.54 가� 주식 단위� 부여받았음� 공개했습니다. � 단위� $408.28� 가치가 있으�, 이사가 이사회에� 물러나거� 지배권 변� � 1대 1 비율� 보통주로 전환됩니�. 이번 부� � Johnson은 � 474.05 주식 등가 단위� 보유하고 있으�, 모두 직접 소유� 기록되어 있습니다.

이번 거래� 분기� 이사� 보수� 정기� 이연� 나타내며, 공개 시장에서� 매매가 아닙니다. � $31�� 추정 시가총액으로 Thermo Fisher� 수십� 달러 규모 시장가치에 비해 재무적으� 미미� 수준입니�. 옵션 행사� 없었�, 보통� 매도� 없었으며 회사� 주식 수와 현금 상태� 변동이 없습니다. 그럼에도 이번 제출은 Johnson� 보상 일부� 미래 주주 수익� 연계하여 인센티브 정렬� 강화합니�.

Thermo Fisher Scientific Inc. (TMO) a déposé un formulaire 4 le 1er juillet 2025, révélant que la directrice Jennifer M. Johnson a reçu 76,54 unités d'actions fantômes le 28 juin 2025 dans le cadre du Plan de rémunération différée pour les administrateurs de la société. Ces unités, valorisées à 408,28 $ chacune, se convertissent en actions ordinaires au taux de 1 pour 1 lorsque la directrice quitte le conseil d'administration ou en cas de changement de contrôle. Après cet attribution, Johnson détient 474,05 unités équivalentes en actions, toutes enregistrées en propriété directe.

Cette opération représente un report habituel des honoraires trimestriels du conseil d'administration, et non un achat ou une vente sur le marché ouvert. Avec une valeur marchande estimée à environ 31 000 $, cette déclaration est financièrement négligeable par rapport à la capitalisation boursière multimilliardaire de Thermo Fisher. Aucune option n’a été exercée, aucune action ordinaire vendue, et le nombre d’actions ainsi que la trésorerie de la société restent inchangés. Néanmoins, cette déclaration renforce l’alignement des incitations en liant une partie de la rémunération de Johnson aux futurs rendements pour les actionnaires.

Thermo Fisher Scientific Inc. (TMO) reichte am 1. Juli 2025 ein Formular 4 ein und gab bekannt, dass die Direktorin Jennifer M. Johnson am 28. Juni 2025 76,54 Phantomaktieneinheiten im Rahmen des Deferred Compensation Plans für Direktoren erhalten hat. Die Einheiten, die jeweils mit 408,28 $ bewertet sind, werden bei Ausscheiden der Direktorin aus dem Vorstand oder bei einem Kontrollwechsel im Verhältnis 1:1 in Stammaktien umgewandelt. Nach der Gutschrift hält Johnson 474,05 aktienäquivalente Einheiten, die alle als Direktbesitz verbucht sind.

Die Transaktion stellt eine routinemäßige Aufschiebung der vierteljährlichen Vorstandsvergütung dar und ist kein Kauf oder Verkauf am freien Markt. Bei einem geschätzten Marktwert von rund 31.000 $ ist die Meldung im Verhältnis zur milliardenschweren Marktkapitalisierung von Thermo Fisher finanziell unerheblich. Es wurden keine Optionen ausgeübt, keine Stammaktien verkauft, und die Anzahl der Aktien sowie die Liquiditätslage des Unternehmens bleiben unverändert. Die Meldung stärkt jedoch die Anreizstruktur, indem ein Teil von Johnsons Vergütung an zukünftige Aktionärsrenditen gekoppelt wird.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
GLASSCOCK LARRY C

(Last) (First) (Middle)
8930 BAY COLONY DRIVE, APT. 901

(Street)
NAPLES FL 34108

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SIMON PROPERTY GROUP INC /DE/ [ SPG ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/30/2025 P(1) 396 A $159.29(1) 43,185 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares of common stock acquired through the reinvestment of dividends received on restricted stock awarded to the Reporting Person as non-cash compensation under the Simon Property Group, L.P. 2019 Stock Incentive Plan.
/s/ Larry C. Glasscock by his attorney-in-fact, Steven E. Fivel 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Thermo Fisher (TMO) shares did Jennifer M. Johnson acquire?

She was credited with 76.54 phantom stock units, convertible 1-for-1 into common shares.

What price was used to credit the phantom stock units?

Units were valued at $408.28 each, based on the quarter-end closing price.

What is Johnson’s total TMO beneficial ownership after the transaction?

Her deferred account now holds 474.05 common-stock equivalent units.

Is this an open-market purchase of Thermo Fisher shares?

No. The units were issued through the Deferred Compensation Plan for Directors, not bought on the open market.

When can the phantom stock units be converted to common stock?

They convert upon cessation of director service or a change of control of the company.
Simon Prop Grp

NYSE:SPG

SPG Rankings

SPG Latest News

SPG Latest SEC Filings

SPG Stock Data

52.45B
320.39M
1.83%
94.55%
1.31%
REIT - Retail
AG˹ٷ Estate Investment Trusts
United States
INDIANAPOLIS